Nascent Biotech Gains On Encouraging Pritumumab Data From Preclinical Studies

by Vandana Singh, Benzinga Editor

February 17, 2021 11:44 AM | 1 min read | Make a Comment

Nascent Biotech Inc NBIO has announced the publication of promising in-vitro study results from its pritumumab (PTB) research collaboration with Syracuse University, validating the potential for PTB for COVID-19 symptoms.
The data showed that pritumumab successfully blocked 80% of viral entry into cells. Now PTB will be advanced to laboratory-based animal studies.
Nascent is currently developing methods to treat viral infections along with a traditional vaccine platform.
Besides, Nascent recently opened its Phase 1 trial for Brain Cancer at Hoag Family Cancer Institute and Pickup Family Neurosciences Institute Presbyterian, and additional updates are anticipated soon.
Price Action: NBIO gained 60% at $0.14 in market trading hours on the last check Wednesday.

Posted In: Biotech News FDA General Covid-19

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.